Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200, and 250 mg/ Day) as Adjunctive Therapy in Adults With Schizophrenia

NCT00772005 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00772005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00772005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200, and 250 mg/ Day) as Adjunctive Therapy in Adults With Schizophrenia
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2008
Completion date
May 31, 2010
Enrollment
287 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia